The report found that just over 2% of adults in the U.S. took a GLP-1 to treat obesity or overweight in 2024, up from just 0.3% in 2019. This is a relative increase of 586.7%, according to the ...

Wegovy and other GLP-1 obesity and blood sugar control drugs accounted for 17% of pharmacy benefits spending at CBIZ employer clients with self-funded health plans in 2024, up from 13% in 2023 ...

Gastrointestinal issues are common in patients taking GLP-1 weight loss drugs like Ozempic and Wegovy, but there are some lesser known side effects that range from bothersome to bizarre.

GLP-1s are reshaping the landscape of obesity treatment, but it's clear that medication alone is not a complete solution. This consensus-based guidance highlights the critical role of nutrition in ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded.

Compounded GLP-1 drugs aren't FDA-approved and may carry unknown safety risks. Experts warn of inconsistent quality, dosing and possible side effects in compounded meds. Lifestyle habits—like ...

People using GLP-1 drugs like Ozempic are reporting "Ozempic teeth," an unusual side effect impacting dental health. "Ozempic teeth" may involve tooth decay, sensitivity, and tooth loss. Dentists ...

Glucagon-like peptide-1 agonists are a class of medications historically used to treat type 2 diabetes and manage blood sugar. In recent years, some of these drugs have also been approved to treat ...

NEW YORK, June 04, 2025--IFF (NYSE: IFF), a global leader in food, beverage, and health and wellness, has released a new report highlighting how the rapidly growing GLP-1 consumer market is ...

Most famous for its canal, Panama’s namesake capital has been busily reinventing itself. Explore the storied spaces of its old quarter, pockets of urban greenery and vibrant restaurant scene.

ORLANDO — Primary care providers can use a new clinical advisory guideline to nutritionally support patients who are using GLP-1 receptor agonists, according to experts.The joint advisory was ...